ArticleOphthalmology2012
Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.
Article in Ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Sandwich therapy combining photodynamic therapy and adjunctive anti-VEGF for juxtapapillary retinal capillary hemangioblastoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Parapapillary retinal hemangioblastoma presenting as an epiretinal membrane in a patient with Von Hippel-Lindau disease: a case report.Frontiers in medicine · 2026Article
- Clinical benefits of laser therapy in von hippel-lindau syndrome: improved vision and reduced complications.American journal of cancer research · 2025Article
- ZEISS PLEX Elite 9000 Widefield Optical Coherence Tomography Angiography as Screening Method for Early Detection of Retinal Hemangioblastomas in von Hippel-Lindau Disease.Translational vision science & technology · 2024Article
- Optic nerve and chiasm hemangioblastomas in von Hippel-Lindau disease: report of 12 cases and review of the literature.Frontiers in oncology · 2024Article
- 3-D OCT angiographic evidence of Anti-VEGF therapeutic effects on retinal capillary hemangioma.American journal of ophthalmology case reports · 2022Article
- Review
- Intrafamilial Variability of Ocular Manifestations of von Hippel-Lindau Disease.Ophthalmology. Retina · 2022Article
- Longitudinal Swept-Source OCT Angiography of Juxtapapillary Retinal Capillary Hemangioblastoma.Ophthalmology. Retina · 2020Article
- Retinal capillary hemangioblastomatosis and renal tumor in Von Hippel-Lindau disease.American journal of ophthalmology case reports · 2020Article
- Detection of retinal microvascular changes in von Hippel-Lindau disease using optical coherence tomography angiography.PloS one · 2020Article
- Photocoagulation for juxtapapillary retinal hemangioma in a young girl: A case report.Molecular and clinical oncology · 2019Article
- Von Hippel-Lindau disease.Handbook of clinical neurology · 2015Review
- Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With Von Hippel-Lindau Disease.Journal of vitreoretinal diseasesArticle
- Risk Analysis of Retinal Hemangioblastomas in Nonadvanced Stages of von Hippel-Lindau Syndrome Using Ultra-widefield Imaging: The ULTRA von Hippel-Lindau Study.Ophthalmology scienceArticle
- Von Hippel-Lindau Disease and the Eye.Journal of ophthalmic & vision researchReview
- Tractional retinal detachment and juxtapapillary retinal capillary hemangioma in a 6-year-old girl: A case report.Oman journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveCharacterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression.
designRetrospective analysis of a case series from a longitudinal, observational study.
participantsTwo hundred forty-nine participants with clinically defined systemic VHL disease and more than 2 years of ophthalmic follow-up.
methodsStandardized scoring of ocular phenotype and systemic characteristics was performed at each study visit and was analyzed longitudinally to determine progression of ocular VHL disease.
main outcome measuresMeasures evaluated include: visual acuity, features of ocular VHL disease (presence, location, number, and extent of retinal capillary hemangioblastomas [RCHs]), germline mutation in the VHL gene, demographics (age, gender, age at onset of ocular disease), and patient characteristics (smoking status, body mass index).
resultsMost participants demonstrated relative anatomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2 ± 4.0 years. Approximately three quarters (73%) of participants without ocular VHL disease at baseline remained disease free at the end of follow-up. Among eyes with ocular VHL disease at baseline, 88% did not demonstrate RCHs in a new retinal location, 70% remained stable in RCH number, and 79% remained stable in the extent of RCH involvement. Mean visual acuity for all study eyes (n = 498) decreased by 5.1 ± 0.6 letters across follow-up, with 16.1% of study eyes decreasing by more than 10 letters in visual acuity. Among eyes affected at baseline, greater vision loss was associated with the presence of juxtapapillary RCHs, development of RCH in a new location, and increase in peripheral RCH number and extent. Younger baseline age, younger age at onset of ocular VHL disease, involvement of the fellow eye with ocular VHL disease, and missense or protein-truncating germline mutations were associated significantly with increased anatomic involvement and functional deterioration.
conclusionsPatients with ocular VHL disease maintain relative anatomic and functional stability, with only a minority demonstrating marked anatomic progression and vision loss. Systemic and ocular risk factors for anatomic progression and vision loss can help practitioners identify patients with a higher risk profile for counseling, closer follow-up, and proactive treatment. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.